<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7239338\results\search\disease\results.xml">
  <result pre="CÃ´te dâ€™IvoireAbidjanCÃ´te dâ€™Ivoire[5], Bernhardâ€�Nochtâ€�Institute for Tropical MedicineHamburgGermany[6], German Center for" exact="Infection" post="Research (DZIF)Partner Site HamburgGermany[7], Centre Hospitalier Universitaire de BordeauxBordeauxFrance[8],"/>
  <result pre="the context of Ebola virus, but also for other emerging" exact="viral" post="diseases for which no therapeutics are available. fig-count: table-count:"/>
  <result pre="a very narrow range of only nine human viruses (HIV," exact="hepatitis C" post="virus (HCV), herpes simplex virus, influenza, hepatitis B virus,"/>
  <result pre="of only nine human viruses (HIV, hepatitis C virus (HCV)," exact="herpes" post="simplex virus, influenza, hepatitis B virus, Varicella zoster virus,"/>
  <result pre="viruses (HIV, hepatitis C virus (HCV), herpes simplex virus, influenza," exact="hepatitis" post="B virus, Varicella zoster virus, human cytomegalovirus, respiratory syncytial"/>
  <result pre="virus (HCV), herpes simplex virus, influenza, hepatitis B virus, Varicella" exact="zoster" post="virus, human cytomegalovirus, respiratory syncytial virus, and human papillomavirus),"/>
  <result pre="virus, influenza, hepatitis B virus, Varicella zoster virus, human cytomegalovirus," exact="respiratory" post="syncytial virus, and human papillomavirus), with antiâ€�HIV and antiâ€�HCV"/>
  <result pre="the cost of drug development and the epidemiology of these" exact="infections" post="that mostly affect lowâ€�income countries, it is unlikely that"/>
  <result pre="research groups to look for innovative antiviral strategies against emerging" exact="viral" post="infections. In the last years, our group was involved"/>
  <result pre="against a variety of other RNA viruses, in particular Ebola," exact="Lassa fever," post="Marburg, Nipah, and Zika viruses.7, 8, 9 The main"/>
  <result pre="as the antiviral efficacy of a repurposed drug can be" exact="lower" post="than what could be obtained with a specific antiviral"/>
  <result pre="specific antiviral agent. Following what has been done for other" exact="chronic" post="or acute viral infections,11, 12, 13 we here show"/>
  <result pre="agent. Following what has been done for other chronic or" exact="acute" post="viral infections,11, 12, 13 we here show how the"/>
  <result pre="Following what has been done for other chronic or acute" exact="viral" post="infections,11, 12, 13 we here show how the techniques"/>
  <result pre="been instrumental to better understand the immuneâ€�pathogenesis of Ebola virus" exact="disease" post="(EVD) and to optimize the use of favipiravir. In"/>
  <result pre="other emerging viruses. EBOLA VIRUS DISEASE EVD is caused by" exact="infection" post="with a virus of the family Filoviridae, genus Ebolavirus."/>
  <result pre="to develop animal models of the disease. Depending on the" exact="viral" post="strain and available medical care, case fatality rate ranges"/>
  <result pre="West Africa outbreak. After an incubation period of 2â€&quot;21Â days," exact="symptomatic" post="patients enter an acute phase of infection during which"/>
  <result pre="an incubation period of 2â€&quot;21Â days, symptomatic patients enter an" exact="acute" post="phase of infection during which they are highly contagious.14"/>
  <result pre="of 2â€&quot;21Â days, symptomatic patients enter an acute phase of" exact="infection" post="during which they are highly contagious.14 Early symptoms include"/>
  <result pre="include fever, asthenia, myalgia, which then evolve to severe gastrointestinal" exact="syndrome" post="and possibly multiâ€�organ failure leading to severe renal impairment,"/>
  <result pre="infection, but then infects monocytes, hepatocytes, adrenocortical cells, fibroblast, and" exact="epithelial" post="cells.18, 19In vitro experiments suggest that the eclipse phase"/>
  <result pre="by activated monocytes/macrophages.22 Consistent with EVD pathogenesis, high levels of" exact="viral" post="load and cytokines (IL6, IL10, IL1Î², TNFÎ±, MIP1Î±, MIP1Î²,"/>
  <result pre="patients,28 suggesting that the adaptive immune response is involved in" exact="viral" post="clearance. FAVIPIRAVIR IN HUMANS INFECTED WITH EVD The 2013â€&quot;2016"/>
  <result pre="inhibitor approved in Japan for the treatment of noncomplicated influenza" exact="infections" post="and in clinical development in the United States. Favipiravir"/>
  <result pre="90%), a low distribution volume (~Â 15Â L), and a" exact="short" post="halfâ€�life (2â€&quot;5Â hours). This drug was characterized by doseâ€�dependent"/>
  <result pre="mediated by aldehyde oxidase, and ethnic discrepancies of exposure, with" exact="lower" post="plasma concentration of ~Â 50% reported in white and"/>
  <result pre="lower plasma concentration of ~Â 50% reported in white and" exact="African" post="patients as compared with Japanese patients.31, 32 Favipiravir was"/>
  <result pre="treated with favipiravir 150Â mg/kg b.i.d. initiated 6Â days after" exact="viral" post="challenge.35 PKÂ data from manufacturer allow to identify PK"/>
  <result pre="average and trough concentrations (83.3 and 57Â Âµg/mL, respectively) in" exact="African" post="and white patients as that predicted in mice successfully"/>
  <result pre="day 2 postâ€�treatment initiation, the observed drug concentrations were slightly" exact="lower" post="than the model predictions (median value of 46.1 vs."/>
  <result pre="There was no significant relationship between favipiravir concentrations and EBOV" exact="viral" post="kinetics or mortality. Overall, these results suggested that favipiravir"/>
  <result pre="day 2 and day 4. The reasons why concentrations were" exact="lower" post="than anticipated are not fully understood, but may be"/>
  <result pre="as this model had been built on patients receiving much" exact="lower" post="doses of favipiravir than in the JIKI trial (up"/>
  <result pre="An additional nonexclusive reason could be an effect of the" exact="disease" post="on vital functions, altering the PKs of the drug."/>
  <result pre="the limitations due to the study design, in particular the" exact="absence of" post="a control group, nonhuman primate (NHP) studies were planned"/>
  <result pre="cynomolgus macaques from a Mauritian colony, which well recapitulates the" exact="disease" post="in humans.42 In brief, animals were infected intramuscularly with"/>
  <result pre="Ebola virus Gabon 2001 strain, belonging to Zaire ebolavirus species." exact="Viral" post="load was detectable in most animals at day 3"/>
  <result pre="which the pathogenesis is less rapid; however, the time between" exact="disease" post="onset, defined as the observation of the first clinical"/>
  <result pre="in humans (5Â days).43 Favipiravir 100Â mg/kg b.i.d. slightly reduces" exact="viral" post="load peak but does not significantly increase survival Preliminary"/>
  <result pre="(preâ€�exposure prophylaxis). Although treated animals had a median peak viremia" exact="lower" post="than untreated animals, there was no benefit of favipiravir"/>
  <result pre="experiment). The analysis of drug concentrations revealed levels of exposure" exact="lower" post="than anticipated from PK studies performed by the manufacturer"/>
  <result pre="China, when parallel experiment in noninfected Mauritian cynomolgus also underlined" exact="lower" post="Caverage (10Â Âµg/mL) than the targeted computed from mice"/>
  <result pre="the possibility to use higher doses of favipiravir.8 Table 1" exact="Viral" post="load at D7 in animals infected with 1,000 PFU"/>
  <result pre="subsequent experiments with higher dosing regimens obtained using Eq. 1," exact="viral" post="load observations obtained in subsequent experiments Â Median viral"/>
  <result pre="1, viral load observations obtained in subsequent experiments Â Median" exact="viral" post="load (log10 RNA/mL) Day 5 Day 7 Â Observations"/>
  <result pre="haemorrhagic fever virus; EBOV, Ebola virus; JUNV, Junin virus; LAV," exact="Lassa fever" post="virus; MARV, Marburg virus; RVFV, Rift valley fever virus;"/>
  <result pre="virus; MARV, Marburg virus; RVFV, Rift valley fever virus; YFV," exact="Yellow fever" post="virus. Reproduced from ref. 8. Next, we used these"/>
  <result pre="from ref. 8. Next, we used these predictions and the" exact="viral" post="load already collected in NHPs to elaborate a simplified"/>
  <result pre="in NHPs to elaborate a simplified mathematical model of Ebola" exact="viral" post="dynamics where we assumed no target cell replenishment (such"/>
  <result pre="below), allowing us to derive an approximate solution for the" exact="viral" post="load kinetics to the peak of viremia44: (1) V"/>
  <result pre="+ EC 50 - 1 where V0 is the initial" exact="viral" post="load level, R0 is the basic reproductive number (see"/>
  <result pre="basic reproductive number. Using this simple model to fit the" exact="viral" post="load obtained in untreated NHPs and in those treated"/>
  <result pre="same design (i.e., with treatment starting 2Â days prior to" exact="infection" post="and continuing for 14Â days; i.e., 12Â days postinfection)."/>
  <result pre="14Â days; i.e., 12Â days postinfection). We reported in the" exact="primary" post="analysis the results obtained in animals challenged with 1,000"/>
  <result pre="survival (PÂ Figure 2). Further, we found that favipiravir inhibited" exact="viral" post="replication (molecular and infectious viral loads) in a drug"/>
  <result pre="Further, we found that favipiravir inhibited viral replication (molecular and" exact="infectious" post="viral loads) in a drug concentrationâ€�dependent manner. Remarkably, the"/>
  <result pre="we found that favipiravir inhibited viral replication (molecular and infectious" exact="viral" post="loads) in a drug concentrationâ€�dependent manner. Remarkably, the observed"/>
  <result pre="of the JIKI trial (see above), were associated with reduced" exact="viral" post="loads, lower infectious titers, and extended survival. The mechanism"/>
  <result pre="JIKI trial (see above), were associated with reduced viral loads," exact="lower" post="infectious titers, and extended survival. The mechanism of action"/>
  <result pre="trial (see above), were associated with reduced viral loads, lower" exact="infectious" post="titers, and extended survival. The mechanism of action by"/>
  <result pre="extended survival. The mechanism of action by which favipiravir reduces" exact="viral" post="replication may be direct inhibition of the viral polymerase"/>
  <result pre="favipiravir reduces viral replication may be direct inhibition of the" exact="viral" post="polymerase via chain termination, but also by the dramatic"/>
  <result pre="CONCEPTS ON MODELING VIRAL DYNAMICS AND ANTIVIRAL TREATMENT DURING AN" exact="ACUTE" post="INFECTION The standard model of viral dynamics The basic"/>
  <result pre="ANTIVIRAL TREATMENT DURING AN ACUTE INFECTION The standard model of" exact="viral" post="dynamics The basic model of viral infection in absence"/>
  <result pre="The standard model of viral dynamics The basic model of" exact="viral infection" post="in absence of treatment, called in the following the"/>
  <result pre="standard model of viral dynamics The basic model of viral" exact="infection" post="in absence of treatment, called in the following the"/>
  <result pre="of viral dynamics The basic model of viral infection in" exact="absence of" post="treatment, called in the following the â€œtarget cell limited"/>
  <result pre="absence of treatment, called in the following the â€œtarget cell" exact="limited" post="model,â€� is given by the following set of equations"/>
  <result pre="the basic reproduction number, R0, as the number of cell" exact="infections" post="that occur from a single infected cell at the"/>
  <result pre="from a single infected cell at the beginning of the" exact="infection" post="and given by R 0 = p Î² s"/>
  <result pre="Î´ c . Figure 3 Model structures used to described" exact="acute" post="viral infection dynamicsÂ (a) â€œTarget cell limitedâ€� model of"/>
  <result pre="c . Figure 3 Model structures used to described acute" exact="viral infection" post="dynamicsÂ (a) â€œTarget cell limitedâ€� model of viral dynamics"/>
  <result pre=". Figure 3 Model structures used to described acute viral" exact="infection" post="dynamicsÂ (a) â€œTarget cell limitedâ€� model of viral dynamics"/>
  <result pre="acute viral infection dynamicsÂ (a) â€œTarget cell limitedâ€� model of" exact="viral" post="dynamics considers the interaction between free virions (V) and"/>
  <result pre="this model, polymerase inhibitor, such as favipiravir, act by blocking" exact="viral" post="replication from infected cells with efficacy noted Ïµ. (b)"/>
  <result pre="of cytokines, in particular IFNÎ±, that can decrease the cell" exact="susceptibility to" post="infection, modeled by a compartment of refractory cells (R)."/>
  <result pre="of death, h(t). Modified from ref. 69. Antiviral treatment during" exact="chronic" post="infection During chronic infection, such as HIV or HCV,49,"/>
  <result pre="death, h(t). Modified from ref. 69. Antiviral treatment during chronic" exact="infection" post="During chronic infection, such as HIV or HCV,49, 50"/>
  <result pre="Modified from ref. 69. Antiviral treatment during chronic infection During" exact="chronic" post="infection, such as HIV or HCV,49, 50 where these"/>
  <result pre="or HCV,49, 50 where these models have been mostly used," exact="viral" post="load levels, V, are roughly constant in absence of"/>
  <result pre="mostly used, viral load levels, V, are roughly constant in" exact="absence of" post="treatment and reflect the equilibrium between the process of"/>
  <result pre="of treatment and reflect the equilibrium between the process of" exact="viral" post="production and viral elimination. Likewise, the number of infected"/>
  <result pre="reflect the equilibrium between the process of viral production and" exact="viral" post="elimination. Likewise, the number of infected cells is constant,"/>
  <result pre="elimination by the immune response, is compensated by de novo" exact="infection" post="of target cells that constantly replenish the pool of"/>
  <result pre="the initiation of an antiviral drug may primarily block new" exact="infection" post="with an effectiveness Î·, or block viral production with"/>
  <result pre="primarily block new infection with an effectiveness Î·, or block" exact="viral" post="production with an effectiveness Îµ. These treatment effect parameters"/>
  <result pre="between 0 (no drug effect) and 1 (full suppression). In" exact="chronic" post="infection, the role of an antiviral treatment is to"/>
  <result pre="infection, the role of an antiviral treatment is to reduce" exact="viral" post="replication, making the few remaining virus particles uncapable to"/>
  <result pre="the continuous loss of infected cells and to support infection." exact="Viral" post="clearance can be achieved if treatment effectiveness passes a"/>
  <result pre="needs to be in the order of 90â€&quot;99% to generate" exact="viral" post="clearance. It is remarkable that similar R0 values were"/>
  <result pre="this model, such as the treatment duration, the presence of" exact="viral" post="reservoirs, and the barrier to resistance. Nonetheless, this shows"/>
  <result pre="needed to compensate the impaired immune response and to achieve" exact="viral" post="clearance in chronic infection. Antiviral treatment during acute infection"/>
  <result pre="the impaired immune response and to achieve viral clearance in" exact="chronic" post="infection. Antiviral treatment during acute infection and the role"/>
  <result pre="to achieve viral clearance in chronic infection. Antiviral treatment during" exact="acute" post="infection and the role of the innate immune response"/>
  <result pre="achieve viral clearance in chronic infection. Antiviral treatment during acute" exact="infection" post="and the role of the innate immune response In"/>
  <result pre="and the role of the innate immune response In an" exact="acute" post="infection, such as influenza or EVD, the role of"/>
  <result pre="it can delay the virus growth to such extent that" exact="viral" post="load levels and disease symptoms, which are closely related,54"/>
  <result pre="virus growth to such extent that viral load levels and" exact="disease" post="symptoms, which are closely related,54 can be alleviated, giving"/>
  <result pre="models for the innate and the adaptive immune response to" exact="acute" post="viral infection have been proposed (see for instance refs."/>
  <result pre="for the innate and the adaptive immune response to acute" exact="viral infection" post="have been proposed (see for instance refs. 55, 56"/>
  <result pre="the innate and the adaptive immune response to acute viral" exact="infection" post="have been proposed (see for instance refs. 55, 56"/>
  <result pre="the action of the immune response results in limiting cell" exact="infection" post="(for instance via an interferon (IFN) response, see ref."/>
  <result pre="cells, or also considering the effect of IFN in reducing" exact="viral" post="production.12 Further extensions may include the cellular or humoral"/>
  <result pre="may include the cellular or humoral adaptive immune responses. In" exact="acute" post="infections, most of the proposed adaptive response models focused"/>
  <result pre="explore the mechanisms leading to the outcome of the infection," exact="viral" post="clearance, host death, or chronic infection. As shown in"/>
  <result pre="to the outcome of the infection, viral clearance, host death," exact="or chronic" post="infection. As shown in Figure 4 (top), the model"/>
  <result pre="the outcome of the infection, viral clearance, host death, or" exact="chronic" post="infection. As shown in Figure 4 (top), the model"/>
  <result pre="model given by Eq. 3 can reproduce the patterns of" exact="viral" post="load observed in clinical data where the peaks of"/>
  <result pre="and cytokines coincide.56, 61 Consistent with the standard model of" exact="viral" post="dynamics, viral decline after peak viremia results from a"/>
  <result pre="coincide.56, 61 Consistent with the standard model of viral dynamics," exact="viral" post="decline after peak viremia results from a lack of"/>
  <result pre="to â€œget first in contactâ€� with the susceptible cells. In" exact="absence of" post="treatment, this race triggers an inflammatory response to counter"/>
  <result pre="this race triggers an inflammatory response to counter the exponential" exact="viral" post="replication and this â€œcytokine stormâ€� is directly related to"/>
  <result pre="initiated at D0 with an effect of 50%, which is" exact="lower" post="than the critical efficacy (here equal to 83%) is"/>
  <result pre="critical efficacy (here equal to 83%) is sufficient to reduce" exact="viral" post="growth, giving time for the IFNÎ± response to put"/>
  <result pre="4 logs. This prediction is different from the target cell" exact="limited" post="model (Eq. 2), where ÎµÂ =Â 50% would impair"/>
  <result pre="limited model (Eq. 2), where ÎµÂ =Â 50% would impair" exact="viral" post="growth and, hence, delay peak viremia, but with only"/>
  <result pre="4 bottom). Figure 4 Effect of an antiviral treatment on" exact="viral" post="dynamics according to the timing of treatment initiation (left:"/>
  <result pre="including an innate immune response (Eq. 3); bottom: target cell" exact="limited" post="model (Eq. 2) according to the timing of treatment"/>
  <result pre="6, and Î¸Â =Â 200Â pg/mL. In the target cell" exact="limited" post="model, q was set to 0. The timing of"/>
  <result pre="peak viremia will have very little or no effect on" exact="viral" post="dynamics.63 In practice, the use of a model integrating"/>
  <result pre="use of a model integrating immune response dynamics has been" exact="limited" post="by the fact that parameter estimation requires to measure"/>
  <result pre="several markers longitudinally (such as IFN and viremia) during the" exact="short" post="period of time where these markers are detectable.56, 64"/>
  <result pre="obviously difficult in humans (due to the difficulty to identify" exact="viral infection" post="before symptoms occur) but also in animal models, due"/>
  <result pre="difficult in humans (due to the difficulty to identify viral" exact="infection" post="before symptoms occur) but also in animal models, due"/>
  <result pre="that can be performed. Of note, in these models, the" exact="viral" post="load does reach 0 (i.e., eradication, only asymptotically, and"/>
  <result pre="these models is that, in case of high antiviral efficacy," exact="viral" post="growth is almost entirely blocked, thus the immune system"/>
  <result pre="and all cells remain targets when treatment is stopped. Because" exact="viral" post="dynamic models are deterministic, it cannot reproduce viral eradication"/>
  <result pre="stopped. Because viral dynamic models are deterministic, it cannot reproduce" exact="viral" post="eradication and even a small quantity of virus can"/>
  <result pre="treatment is stopped, virus dynamics will be similar to an" exact="acute" post="infection without any treatment. To address the question of"/>
  <result pre="is stopped, virus dynamics will be similar to an acute" exact="infection" post="without any treatment. To address the question of treatment"/>
  <result pre="would need to incorporate in these models the possibility of" exact="viral" post="eradication, using stochastic events65 or including a â€œcure boundary,â€�"/>
  <result pre="D25 of 100%, 0%, and 0%, respectively. A target cell" exact="limited" post="model was sufficient to capture the viral kinetic of"/>
  <result pre="A target cell limited model was sufficient to capture the" exact="viral" post="kinetic of the acute infection, consistent with the fact"/>
  <result pre="model was sufficient to capture the viral kinetic of the" exact="acute" post="infection, consistent with the fact that IFN response is"/>
  <result pre="the fact that IFN response is impaired in these animals.68" exact="Viral" post="kinetics in untreated animals was characterized by an exponential"/>
  <result pre="treatment efficacy larger than 90% would be needed to block" exact="viral" post="replication. Viral growth was accompanied with high levels of"/>
  <result pre="larger than 90% would be needed to block viral replication." exact="Viral" post="growth was accompanied with high levels of transaminases,33 suggesting"/>
  <result pre="cell loss, and accordingly the halfâ€�life of infected cells was" exact="short" post="and estimated to about 6Â hours (e.g., Î´Â =Â"/>
  <result pre="delay observed between the drug administration and the beginning of" exact="viral" post="decline, we assumed an effect compartment between drug concentration"/>
  <result pre="sufficient (estimated to 80% at peak viremia) to substantially perturb" exact="viral" post="dynamics and increase survival. This suggests that favipiravir treatment,"/>
  <result pre="IFNÎ³, and Gâ€�CSF, were more significantly associated with survival than" exact="viral" post="load levels, suggesting that those cytokines may be more"/>
  <result pre="that those cytokines may be more predictive of outcome than" exact="viral" post="load. Furthermore, in the four animals that had an"/>
  <result pre="and NKp80) increase showed a trend to be associated to" exact="viral" post="load decline after D10. As described in Section â€œMathematical"/>
  <result pre="manner, which, as explained in Section â€œGeneral concepts on modeling" exact="viral" post="dynamics and antiviral treatment during an acute infectionâ€�, cannot"/>
  <result pre="concepts on modeling viral dynamics and antiviral treatment during an" exact="acute" post="infectionâ€�, cannot be satisfactorily explained by a basic target"/>
  <result pre="cells.58, 71 To identify the most relevant cytokine associated with" exact="viral" post="dynamics, we successively fitted the model to viral load"/>
  <result pre="associated with viral dynamics, we successively fitted the model to" exact="viral" post="load data and each cytokine found significantly associated with"/>
  <result pre="incorporated in models (i), (ii), and (iii) (leading to a" exact="total" post="of 12 possible candidate models), whereas IFNÎ³ was used"/>
  <result pre="(iv). Models assuming that proâ€�inflammatory cytokines increased cell refractoriness to" exact="infection" post="consistently provided the best description of the viral load"/>
  <result pre="refractoriness to infection consistently provided the best description of the" exact="viral" post="load in untreated and treated NHPs, allowing us to"/>
  <result pre="dose effect relationship on viremia compared with the target cell" exact="limited" post="model. Given their high level of correlations, a similarly"/>
  <result pre="high level of correlations, a similarly good fit to the" exact="viral" post="load data could be obtained when assuming that this"/>
  <result pre="of the data description and could reproduce both the cytokineâ€�mediated" exact="lymphopenia" post="observed in early infection and the rapid viral decline"/>
  <result pre="and could reproduce both the cytokineâ€�mediated lymphopenia observed in early" exact="infection" post="and the rapid viral decline in NHPs after peak"/>
  <result pre="the cytokineâ€�mediated lymphopenia observed in early infection and the rapid" exact="viral" post="decline in NHPs after peak viremia. The schematic representation"/>
  <result pre="after peak viremia. The schematic representation of the final selected" exact="viral" post="dynamic model is given in Figure 3c. Impact of"/>
  <result pre="viral dynamic model is given in Figure 3c. Impact of" exact="viral" post="dynamics and cytokine storm on disease progression Finally, we"/>
  <result pre="Figure 3c. Impact of viral dynamics and cytokine storm on" exact="disease" post="progression Finally, we used previous developments in the field"/>
  <result pre="developments in the field of joint modeling74, 75 to model" exact="disease" post="dynamics (i.e., viral load and cytokine dynamics) and survival."/>
  <result pre="field of joint modeling74, 75 to model disease dynamics (i.e.," exact="viral" post="load and cytokine dynamics) and survival. Joint modeling is"/>
  <result pre="disease dynamics (i.e., viral load and cytokine dynamics) and survival." exact="Joint" post="modeling is a statistical approach that aims to estimate"/>
  <result pre="is the maximal instantaneous rate of death, X is the" exact="viral" post="load or cytokine levels, and Xe(t) is the lagâ€�value"/>
  <result pre="or cytokine levels, and Xe(t) is the lagâ€�value of the" exact="viral" post="load or cytokine, and X50 value leading to 50%"/>
  <result pre="the hazard function to be dependent on IFNÎ± rather than" exact="viral" post="load provided the best description of the time to"/>
  <result pre="to death (Figure 5), suggesting that cytokine storm, rather than" exact="viral" post="replication per se, was the main driver of death."/>
  <result pre="additional benefit for cell protection. Thus, in untreated animals, the" exact="infection" post="affects a significant proportion of the target cells, and"/>
  <result pre="of limiting cell infection. Conversely, in treated animals, favipiravir reduces" exact="viral" post="production and slows the infection progression. Hence, the number"/>
  <result pre="in treated animals, favipiravir reduces viral production and slows the" exact="infection" post="progression. Hence, the number of infected cells and IFNÎ±"/>
  <result pre="cell protection than in untreated macaques. The impairment of the" exact="viral" post="replication in treated macaques gives time to the organism"/>
  <result pre="to about 3Â days (Î´Â =Â 0.22/day), suggesting that in" exact="absence of" post="an adaptive response, it would take several weeks to"/>
  <result pre="obtained in animals treated with 10Â mg/kg 3Â days after" exact="viral" post="challenge (Figure 6).4 However, treatment given after D5 would"/>
  <result pre="the drug PK/pharmacodynamic (PD) could also be useful in other" exact="viral" post="infections for which favipiravir has shown antiviral efficacy in"/>
  <result pre="drug PK/pharmacodynamic (PD) could also be useful in other viral" exact="infections" post="for which favipiravir has shown antiviral efficacy in vitro"/>
  <result pre="in vitro or in vivo. Combining favipiravir and ribavirin in" exact="Lassa fever" post="Favipiravir was also reported to have antiviral effect on"/>
  <result pre="fever Favipiravir was also reported to have antiviral effect on" exact="Lassa fever" post="virus, providing 100% protection in the lethal NHP model"/>
  <result pre="which prompted its use to treat several patients with severe" exact="Lassa fever" post="virus infection.78 In order to better understand how ribavirin"/>
  <result pre="and, therefore, the model used was a simple target cell" exact="limited" post="model. In order to gain information on the potential"/>
  <result pre="as a mutagen limiting the infectivity of virions; (ii) reduce" exact="viral" post="production; (iii) reduce cell loss by limiting inflammation; and"/>
  <result pre="immunity. Using these models, we consistently estimated an R0 of" exact="Lassa fever" post="virus of about 5â€&quot;6, and an efficacy of favipiravir"/>
  <result pre="all doses considered, consistent with our results obtained for Ebola" exact="infection" post="in mice.80 Our analyses did not find a statistically"/>
  <result pre="not find a statistically significant effect of ribavirin in reducing" exact="viral" post="production, however, the best description to the data was"/>
  <result pre="from dying. This possibly explains why the AST levels remained" exact="lower" post="in ribavirinâ€�treated mice and could also explain the viral"/>
  <result pre="remained lower in ribavirinâ€�treated mice and could also explain the" exact="viral" post="plateau observed at peak viremia in ribavirin monotherapy group.80"/>
  <result pre="did not act much as a direct antiviral against Lassa" exact="virus infection," post="but rather by reducing the elimination of infected cells,"/>
  <result pre="Âµg/mL, respectively.7, 8 Interestingly these levels are markedly 2â€&quot;10 times" exact="lower" post="than what has been reported for EBOV,31 suggesting that"/>
  <result pre="group of James Whitney published the first model of Zika" exact="viral" post="dynamics in NHPs.81 By using the target cell limited"/>
  <result pre="Zika viral dynamics in NHPs.81 By using the target cell" exact="limited" post="model (Eq. 2), the parameters of Zika viral dynamics"/>
  <result pre="target cell limited model (Eq. 2), the parameters of Zika" exact="viral" post="dynamics could be estimated, in particular R0 found equal"/>
  <result pre="equal to 10.7.7 Then, the effect of favipiravir on blocking" exact="viral" post="production was plugged into this model assuming a dosing"/>
  <result pre="7). Given that peak viremia occurred 2â€&quot;3Â days after subcutaneous" exact="infection" post="in this animal model, the window for treatment is"/>
  <result pre="later than day 1 to have a strong effect on" exact="systemic" post="levels of viruses, at least in NHPs. In humans,"/>
  <result pre="systemic levels of viruses, at least in NHPs. In humans," exact="lower" post="viremia levels are often observed58, 82, 83 and the"/>
  <result pre="as favipiravir penetrates the sexual compartments and crosses the blood" exact="brain" post="barrier,31 an important benefit of the treatment may be"/>
  <result pre="use in pregnant women, it might be of interest for" exact="symptomatic" post="severe central nervous system injury in adults with acute"/>
  <result pre="pregnant women, it might be of interest for symptomatic severe" exact="central nervous system" post="injury in adults with acute infections. However, the impact"/>
  <result pre="for symptomatic severe central nervous system injury in adults with" exact="acute" post="infections. However, the impact of the timing initiation on"/>
  <result pre="on the kinetics in these compartments is unknown. Figure 7" exact="Viral" post="dynamic predictions in Zika infections. Left: Prophylactic treatment assuming"/>
  <result pre="was also recently evaluated in an NHP model of Marburg" exact="infection" post="treated in prophylaxis. Interestingly, although the 6 untreated animals"/>
  <result pre="to peak viremia, may nonetheless have an impact on the" exact="disease" post="and survival. In the 2013â€&quot;2016 outbreak, the time from"/>
  <result pre="was between 3 and 5Â days37, 86 when the maximal" exact="viral" post="load at admission was 4â€&quot;5Â days after symptom onset.43"/>
  <result pre="association of the duration of symptoms before admission and the" exact="lower" post="viral load at baseline to survival88 suggest that their"/>
  <result pre="of the duration of symptoms before admission and the lower" exact="viral" post="load at baseline to survival88 suggest that their efficacy"/>
  <result pre="treatment initiation, and monoclonal antibodies remain uneasy to use in" exact="limited" post="resource settings and expensive to produce. In that respect,"/>
  <result pre="In that respect, and following what has been done in" exact="chronic" post="viral infections, mathematical modeling can be used to better"/>
  <result pre="that respect, and following what has been done in chronic" exact="viral" post="infections, mathematical modeling can be used to better understand"/>
  <result pre="may meet the request of field teams during the Western" exact="African" post="EVD outbreak to propose an early oral treatment to"/>
  <result pre="be complementary to it, for exposed people. The promising vesicular" exact="stomatitis" post="virusâ€�based vaccine used in Guinea provided high level protection"/>
  <result pre="laboratory or clinical evidence of EBOV infection, but whether any" exact="infections" post="were prevented by the use of postexposure prophylaxis is"/>
  <result pre="is not possible to determine from this small number of" exact="uncontrolled" post="cases.92 There remains, more generally, to find drug combinations"/>
  <result pre="against EBOV, as no gain in terms of survival or" exact="viral" post="replication was found in animals receiving the combination as"/>
  <result pre="the promising effects on favipiravir in the NHP model of" exact="Marburg disease" post="encouraged the implementation of a clinical trial targeting exposed"/>
  <result pre="promising effects on favipiravir in the NHP model of Marburg" exact="disease" post="encouraged the implementation of a clinical trial targeting exposed"/>
  <result pre="in the framework of Research Program on Emerging and Reâ€�emerging" exact="Infectious" post="Diseases of the Japan Agency for Medical Research and"/>
  <result pre="the framework of Research Program on Emerging and Reâ€�emerging Infectious" exact="Diseases" post="of the Japan Agency for Medical Research and Development"/>
  <result pre="References 1Marston, H.D., Folkers, G.K., Morens, D.M. &amp;amp; Fauci, A.S.Emerging" exact="viral" post="diseases: confronting threats with new technologies. Sci. Transl. Med.6,"/>
  <result pre="381â€&quot;385 (2016).26934220 5Warren, T.et alEfficacy of galidesivir against Ebola virus" exact="disease" post="in rhesus monkeys. Open Forum Infect. Dis.4, S302 (2017)."/>
  <result pre="Infect. Dis.4 (suppl. 1), S55 (2017). 7Best, K.et alZika plasma" exact="viral" post="dynamics in nonhuman primates provides insights into early infection"/>
  <result pre="plasma viral dynamics in nonhuman primates provides insights into early" exact="infection" post="and antiviral strategies. Proc. Natl. Acad. Sci.114, 8847â€&quot;8852 (2017).28765371"/>
  <result pre="combination with ribavirin in a lethal, immunocompetent mouse model for" exact="Lassa fever." post="J. Infect. Dis.213, 934â€&quot;938 (2016).26531247 10Pushpakom, S.et alDrug repurposing:"/>
  <result pre="H.E., Tricou, V., Chau, N.V.V., Simmons, C.P. &amp;amp; Ferguson, N.M.Withinâ€�host" exact="viral" post="dynamics of dengue serotype 1 infection. J. R. Soc."/>
  <result pre="Macken, C.A., Hayden, F.G. &amp;amp; Perelson, A.S.Kinetics of influenza A" exact="virus infection" post="in humans. J. Virol.80, 7590â€&quot;7599 (2006).16840338 13Smith, A.M.et alKinetics"/>
  <result pre="C.A., Hayden, F.G. &amp;amp; Perelson, A.S.Kinetics of influenza A virus" exact="infection" post="in humans. J. Virol.80, 7590â€&quot;7599 (2006).16840338 13Smith, A.M.et alKinetics"/>
  <result pre="antivirals. Antiviral Res.99, 207â€&quot;213 (2013).23751367 22Caballero, I.S.et alIn vivo Ebola" exact="virus infection" post="leads to a strong innate response in circulating immune"/>
  <result pre="Antiviral Res.99, 207â€&quot;213 (2013).23751367 22Caballero, I.S.et alIn vivo Ebola virus" exact="infection" post="leads to a strong innate response in circulating immune"/>
  <result pre="Padilla, C., Baize, S. &amp;amp; Leroy, E.M.Human fatal Zaire Ebola" exact="virus infection" post="is associated with an aberrant innate immunity and with"/>
  <result pre="C., Baize, S. &amp;amp; Leroy, E.M.Human fatal Zaire Ebola virus" exact="infection" post="is associated with an aberrant innate immunity and with"/>
  <result pre="(2010).20957152 25Ruibal, P.et alUnique human immune signature of Ebola virus" exact="disease" post="in Guinea. Nature533, 100â€&quot;104 (2016).27147028 26Vernet, M.â€�A.et alClinical, virological,"/>
  <result pre="alClinical, virological, and biological parameters associated with outcomes of Ebola" exact="virus infection" post="in Macenta, Guinea. JCI Insight2, e88864 (2017).28352651 27Reynard, S.et"/>
  <result pre="virological, and biological parameters associated with outcomes of Ebola virus" exact="infection" post="in Macenta, Guinea. JCI Insight2, e88864 (2017).28352651 27Reynard, S.et"/>
  <result pre="disease. JCI Insight4, pii: 125106 (2019). 28McElroy, A.K.et alHuman Ebola" exact="virus infection" post="results in substantial immune activation. Proc. Natl. Acad. Sci."/>
  <result pre="JCI Insight4, pii: 125106 (2019). 28McElroy, A.K.et alHuman Ebola virus" exact="infection" post="results in substantial immune activation. Proc. Natl. Acad. Sci."/>
  <result pre="(English version). &amp;lt;https://www.pmda.go.jp/files/000210319.pdf&amp;gt;. 33Oestereich, L.et alSuccessful treatment of advanced Ebola" exact="virus infection" post="with Tâ€�705 (favipiravir) in a small animal model. Antiviral"/>
  <result pre="version). &amp;lt;https://www.pmda.go.jp/files/000210319.pdf&amp;gt;. 33Oestereich, L.et alSuccessful treatment of advanced Ebola virus" exact="infection" post="with Tâ€�705 (favipiravir) in a small animal model. Antiviral"/>
  <result pre="S.J.et alPostâ€�exposure efficacy of oral Tâ€�705 (Favipiravir) against inhalational Ebola" exact="virus infection" post="in a mouse model. Antiviral Res.104, 153â€&quot;155 (2014).24462697 35MentrÃ©,"/>
  <result pre="alPostâ€�exposure efficacy of oral Tâ€�705 (Favipiravir) against inhalational Ebola virus" exact="infection" post="in a mouse model. Antiviral Res.104, 153â€&quot;155 (2014).24462697 35MentrÃ©,"/>
  <result pre="(2015). 37Sissoko, D.et alExperimental treatment with favipiravir for Ebola virus" exact="disease" post="(the JIKI Trial): a historically controlled, singleâ€�arm proofâ€�ofâ€�concept trial"/>
  <result pre="pharmacokinetics in Ebolaâ€�Infected patients of the JIKI trial reveals concentrations" exact="lower" post="than targeted. PLoS Negl. Trop. Dis.11, e0005389 (2017).28231247 42Piorkowski,"/>
  <result pre="G.et alImplementation of a nonâ€�human primate model of Ebola disease:" exact="Infection" post="of Mauritian cynomolgus macaques and analysis of virus populations."/>
  <result pre="to evaluate the baseline case fatality ratio of Ebola virus" exact="disease" post="and inform treatment studies: a retrospective cohort study. PLoS"/>
  <result pre="T. &amp;amp; Nakamura, T.Favipiravir (Tâ€�705), a broad spectrum inhibitor of" exact="viral" post="RNA polymerase. Proc. Jpn. Acad. Ser. B Phys. Biol."/>
  <result pre="cynomolgus macaques. PLoS Med.15, e1002535 (2018).29584730 48Neumann, A.U.et alHepatitis C" exact="viral" post="dynamics in vivo and the antiviral efficacy of interferonâ€�alpha"/>
  <result pre="antiviral efficacy of interferonâ€�alpha therapy. Science282, 103â€&quot;107 (1998).9756471 49Perelson, A.S.Modelling" exact="viral" post="and immune system dynamics. Nat. Rev. Immunol.2, 28â€&quot;36 (2002).11905835"/>
  <result pre="Nat. Rev. Immunol.2, 28â€&quot;36 (2002).11905835 50Perelson, A.S. &amp;amp; Guedj, J.Modelling" exact="hepatitis C" post="therapyâ€�predicting effects of treatment. Nat. Rev. Gastroenterol. Hepatol.12, 437â€&quot;445"/>
  <result pre="Nat. Rev. Gastroenterol. Hepatol.12, 437â€&quot;445 (2015).26122475 51Snoeck, E.et alA comprehensive" exact="hepatitis C" post="viral kinetic model explaining cure. Clin. Pharmacol. Ther.87, 706â€&quot;713"/>
  <result pre="Gastroenterol. Hepatol.12, 437â€&quot;445 (2015).26122475 51Snoeck, E.et alA comprehensive hepatitis C" exact="viral" post="kinetic model explaining cure. Clin. Pharmacol. Ther.87, 706â€&quot;713 (2010).20463660"/>
  <result pre="cure. Clin. Pharmacol. Ther.87, 706â€&quot;713 (2010).20463660 52Whalley, S.A.et alKinetics of" exact="acute" post="hepatitis B virus infection in humans. J. Exp. Med.193,"/>
  <result pre="Clin. Pharmacol. Ther.87, 706â€&quot;713 (2010).20463660 52Whalley, S.A.et alKinetics of acute" exact="hepatitis" post="B virus infection in humans. J. Exp. Med.193, 847â€&quot;854"/>
  <result pre="Ther.87, 706â€&quot;713 (2010).20463660 52Whalley, S.A.et alKinetics of acute hepatitis B" exact="virus infection" post="in humans. J. Exp. Med.193, 847â€&quot;854 (2001).11283157 53Ribeiro, R.M.et"/>
  <result pre="706â€&quot;713 (2010).20463660 52Whalley, S.A.et alKinetics of acute hepatitis B virus" exact="infection" post="in humans. J. Exp. Med.193, 847â€&quot;854 (2001).11283157 53Ribeiro, R.M.et"/>
  <result pre="Exp. Med.193, 847â€&quot;854 (2001).11283157 53Ribeiro, R.M.et alEstimation of the initial" exact="viral" post="growth rate and basic reproductive number during acute HIVâ€�1"/>
  <result pre="the initial viral growth rate and basic reproductive number during" exact="acute" post="HIVâ€�1 infection. J. Virol.84, 6096â€&quot;6102 (2010).20357090 54Carrat, F.et alTime"/>
  <result pre="infection. J. Virol.84, 6096â€&quot;6102 (2010).20357090 54Carrat, F.et alTime lines of" exact="infection" post="and disease in human influenza: a review of volunteer"/>
  <result pre="Virol.84, 6096â€&quot;6102 (2010).20357090 54Carrat, F.et alTime lines of infection and" exact="disease" post="in human influenza: a review of volunteer challenge studies."/>
  <result pre="55Li, Y. &amp;amp; Handel, A.Modeling inoculum dose dependent patterns of" exact="acute" post="virus infections. J. Theor. Biol.347, 63â€&quot;73 (2014).24440713 56Saenz, R.A.et"/>
  <result pre="J. Theor. Biol.347, 63â€&quot;73 (2014).24440713 56Saenz, R.A.et alDynamics of influenza" exact="virus infection" post="and pathology. J. Virol.84, 3974â€&quot;3983 (2010).20130053 57Stetson, D.B. &amp;amp;"/>
  <result pre="Theor. Biol.347, 63â€&quot;73 (2014).24440713 56Saenz, R.A.et alDynamics of influenza virus" exact="infection" post="and pathology. J. Virol.84, 3974â€&quot;3983 (2010).20130053 57Stetson, D.B. &amp;amp;"/>
  <result pre="Opin. Virol.16, 15â€&quot;23 (2016).26590692 59Smith, A.M. &amp;amp; Perelson, A.S.Influenza A" exact="virus infection" post="kinetics: quantitative data and models. Wiley Interdiscip. Rev. Syst."/>
  <result pre="Virol.16, 15â€&quot;23 (2016).26590692 59Smith, A.M. &amp;amp; Perelson, A.S.Influenza A virus" exact="infection" post="kinetics: quantitative data and models. Wiley Interdiscip. Rev. Syst."/>
  <result pre="(2011).21197654 60Perelson, A.S. &amp;amp; Ribeiro, R.M.Modeling the withinâ€�host dynamics of" exact="HIV infection." post="BMC Biol.11, 96 (2013).24020860 61Hayden, F.G.Experimental human influenza: observations"/>
  <result pre="influenza antivirals. Antivir. Ther.17, 133â€&quot;141 (2012).22311616 62Hayden, F.G.et alLocal and" exact="systemic" post="cytokine responses during experimental human influenza A virus infection."/>
  <result pre="alLocal and systemic cytokine responses during experimental human influenza A" exact="virus infection." post="Relation to symptom formation and host defense. J. Clin."/>
  <result pre="defense. J. Clin. Invest.101, 643â€&quot;649 (1998).9449698 63Vegvari, C.et alHow can" exact="viral" post="dynamics models inform endpoint measures in clinical trials of"/>
  <result pre="models inform endpoint measures in clinical trials of therapies for" exact="acute" post="viral infections?PLoS One11, e0158237 (2016).27367230 64Pawelek, K.A.et alModeling withinâ€�host"/>
  <result pre="inform endpoint measures in clinical trials of therapies for acute" exact="viral" post="infections?PLoS One11, e0158237 (2016).27367230 64Pawelek, K.A.et alModeling withinâ€�host dynamics"/>
  <result pre="One11, e0158237 (2016).27367230 64Pawelek, K.A.et alModeling withinâ€�host dynamics of influenza" exact="virus infection" post="including immune responses. PLoS Comput. Biol.8, e1002588 (2012).22761567 65Pearson,"/>
  <result pre="e0158237 (2016).27367230 64Pawelek, K.A.et alModeling withinâ€�host dynamics of influenza virus" exact="infection" post="including immune responses. PLoS Comput. Biol.8, e1002588 (2012).22761567 65Pearson,"/>
  <result pre="65Pearson, J.E., Krapivsky, P. &amp;amp; Perelson, A.S.Stochastic theory of early" exact="viral" post="infection: continuous versus burst production of virions. PLoS Comput."/>
  <result pre="&amp;amp; Perelson, A.S.Modelling how ribavirin improves interferon response rates in" exact="hepatitis C" post="virus infection. Nature432, 922â€&quot;924 (2004).15602565 67Dahari, H.et alHCV kinetic"/>
  <result pre="A.S.Modelling how ribavirin improves interferon response rates in hepatitis C" exact="virus infection." post="Nature432, 922â€&quot;924 (2004).15602565 67Dahari, H.et alHCV kinetic and modeling"/>
  <result pre="treated with favipiravir. Antiviral Res.123, 70â€&quot;77 (2015).26343011 69Madelain, V.et alEbola" exact="viral" post="dynamics in nonhuman primates provides insights into virus immunoâ€�pathogenesis"/>
  <result pre="Ishii, K.J., Coban, C. &amp;amp; Akira, S.Innate immune response to" exact="viral infection." post="Cytokine43, 336â€&quot;341 (2008).18694646 72Helming, L.Inflammation: cell recruitment versus local"/>
  <result pre="Biol.21, R548â€&quot;R550 (2011).21783034 73Shi, C. &amp;amp; Pamer, E.G.Monocyte recruitment during" exact="infection" post="and inflammation. Nat. Rev. Immunol.11, 762â€&quot;774 (2011).21984070 74DesmÃ©e, S.,"/>
  <result pre="antigen kinetics and link with survival in the context of" exact="metastatic" post="prostate cancer: a comparison by simulation of twoâ€�stage and"/>
  <result pre="characterizing the relationship between nonlinear PSA kinetics and survival in" exact="prostate cancer" post="patients. Biometrics73, 305â€&quot;312 (2017).27148956 76Rosenke, K.et alUse of favipiravir"/>
  <result pre="the relationship between nonlinear PSA kinetics and survival in prostate" exact="cancer" post="patients. Biometrics73, 305â€&quot;312 (2017).27148956 76Rosenke, K.et alUse of favipiravir"/>
  <result pre="305â€&quot;312 (2017).27148956 76Rosenke, K.et alUse of favipiravir to treat Lassa" exact="virus infection" post="in macaques. Emerg. Infect. Dis.24, 1696â€&quot;1699 (2018).29882740 77Westover, J.B.et"/>
  <result pre="(2017).27148956 76Rosenke, K.et alUse of favipiravir to treat Lassa virus" exact="infection" post="in macaques. Emerg. Infect. Dis.24, 1696â€&quot;1699 (2018).29882740 77Westover, J.B.et"/>
  <result pre="V.N.et alFavipiravir and ribavirin treatment of epidemiologically linked cases of" exact="Lassa fever." post="Clin. Infect. Dis.65, 855â€&quot;859 (2017).29017278 79Ribeiro, R.M., Laydenâ€�Almer, J.,"/>
  <result pre="K.A., Layden, T.J. &amp;amp; Perelson, A.S.Dynamics of alanine aminotransferase during" exact="hepatitis C" post="virus treatment. Hepatology38, 509â€&quot;517 (2003).12883496 80Carrilloâ€�Bustamante, P.et alDetermining Ribavirinâ€™s"/>
  <result pre="(2003).12883496 80Carrilloâ€�Bustamante, P.et alDetermining Ribavirinâ€™s mechanism of action against Lassa" exact="virus infection." post="Sci. Rep.7, 11693 (2017).28916737 81Osuna, C.E.et alZika viral dynamics"/>
  <result pre="Lassa virus infection. Sci. Rep.7, 11693 (2017).28916737 81Osuna, C.E.et alZika" exact="viral" post="dynamics and shedding in rhesus and cynomolgus macaques. Nat."/>
  <result pre="(2016). 84Osuna, C.E. &amp;amp; Whitney, J.B.Nonhuman primate models of Zika" exact="virus infection," post="immunity, and therapeutic development. J. Infect. Dis.216, S928â€&quot;S934 (2017).29267926"/>
  <result pre="Team . A randomized, controlled trial of ZMapp for Ebola" exact="virus infection." post="N. Engl. J. Med.375, 1448 (2016).27732819 87Investigational Therapeutics for"/>
  <result pre="(2016).27732819 87Investigational Therapeutics for the Treatment of People with Ebola" exact="Virus Disease" post="â€&quot; Full Text View â€&quot; ClinicalTrials.gov. &amp;lt;https://clinicaltrials.gov/ct2/show/NCT03719586&amp;gt;. 88Mulangu, S.et"/>
  <result pre="87Investigational Therapeutics for the Treatment of People with Ebola Virus" exact="Disease" post="â€&quot; Full Text View â€&quot; ClinicalTrials.gov. &amp;lt;https://clinicaltrials.gov/ct2/show/NCT03719586&amp;gt;. 88Mulangu, S.et"/>
  <result pre="&amp;lt;https://clinicaltrials.gov/ct2/show/NCT03719586&amp;gt;. 88Mulangu, S.et alA randomized, controlled trial of Ebola virus" exact="disease" post="therapeutics. N. Engl. J. Med.381, 2293â€&quot;2303 (2019).31774950 89Gomezâ€�Temesio, V."/>
  <result pre="Lancet386, 857â€&quot;866 (2015).26248676 91Marzi, A.et alVSVâ€�EBOV rapidly protects macaques against" exact="infection" post="with the 2014/15 Ebola virus outbreak strain. Science349, 739â€&quot;742"/>
  <result pre="(2017).29153266 93Koizumi, Y.et alQuantifying antiviral activity optimizes drug combinations against" exact="hepatitis C" post="virus infection. Proc. Natl. Acad. Sci. USA114, 1922â€&quot;1927 (2017).28174263"/>
  <result pre="Y.et alQuantifying antiviral activity optimizes drug combinations against hepatitis C" exact="virus infection." post="Proc. Natl. Acad. Sci. USA114, 1922â€&quot;1927 (2017).28174263"/>
 </snippets>
</snippetsTree>
